Combination of selumetinib and erlotinib in NSCLC patients who had progressed to one or prior regimens was also studied in a phase II trial, where patients with neoplasms harboring KRAS mutations were randomized to selumetinib in monotherapy or to the combination arm, whereas patients with KRAS wild-type tumors were randomized to either erlotinib or the combination therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.